@article{article, title  = {{Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial}},

 publisher = {{Elsevier BV}},

 url = {{}},

 year = {{2017}},

 month = {{7}},

 author = {{Cameron D and Morden JP and Canney P and Velikova G and Coleman R and Bartlett J and Agrawal R and Banerji J and Bertelli G and Bloomfield D and Brunt AM et al}},

 doi = {{10.1016/s1470-2045(17)30404-7}},

 volume = {{18}},

 journal = {{The Lancet Oncology}},

 issue = {{7}},

 pages = {{929-945}},

 note = {{Accessed on 2025/10/10}}}